EQ504

About Equillium

Equillium is a public, clinical-stage biotech focused on developing first-in-class therapeutics that selectively modulate the immune system to treat severe autoimmune and inflammatory conditions. Its strategy is built on two core platforms: a Multi-Cytokine Inhibitor platform centered on itolizumab (EQ001) and an Aryl Hydrocarbon Receptor (AhR) modulation platform with EQ504. The company is actively advancing its lead candidate, itolizumab, in Phase 1b trials for aGVHD and lupus/lupus nephritis, targeting significant market opportunities with a differentiated mechanism designed to avoid broad immunosuppression.

Therapeutic Areas